BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease. - Wikidata - awgldk - TriplyDB

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

http://www.wikidata.org/entity/Q45356235

about

The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease Potential therapeutic effects of neurotrophins for acute and chronic neurological diseases The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations Effect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer's Disease Identification of BDNF sensitive electrophysiological markers of synaptic activity and their structural correlates in healthy subjects using a genetic approach utilizing the functional BDNF Val66Met polymorphism.Imago Mundi, Imago AD, Imago ADNI The pro-domains of neurotrophins, including BDNF, are linked to Alzheimer's disease through a toxic synergy with Aβ Future Directions in Imaging Neurodegeneration.Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease.Ketamine administered pregnant rats impair learning and memory in offspring via the CREB pathway.The evolution of preclinical Alzheimer's disease: implications for prevention trials.Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer's disease neurodegeneration Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study.TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting β-amyloidosis in 5XFAD mice.Genetic Risk Score Predicts Late-Life Cognitive Impairment.APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.Brain-Derived Neurotrophic Factor in Alzheimer's Disease: Risk, Mechanisms, and Therapy.Genetic epistasis regulates amyloid deposition in resilient aging.The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia.BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.Inhibition of PDE2 reverses beta amyloid induced memory impairment through regulation of PKA/PKG-dependent neuro-inflammatory and apoptotic pathways The BDNF Val66Met polymorphism moderates the effect of cognitive reserve on 36-month cognitive change in healthy older adults.BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden.Angelica tenuissima Nakai ameliorates cognitive impairment and promotes neurogenesis in mouse model of Alzheimer's disease.An exercise path to preventing Alzheimer's disease: An Editorial Highlight on 'Exercise and BDNF reduce Ab production by enhancing α-secretase processing of APP'.BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.Does BDNF Val66Met contribute to preclinical Alzheimer's disease?Acute Down-regulation of BDNF Signaling Does Not Replicate Exacerbated Amyloid-β Levels and Cognitive Impairment Induced by Cholinergic Basal Forebrain Lesion.Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden.Dissociable influences of APOE ε4 and polygenic risk of AD dementia on amyloid and cognition.BDNF Polymorphism: A Review of Its Diagnostic and Clinical Relevance in Neurodegenerative Disorders.Impact of brain-derived neurotrophic factor genetic polymorphism on cognition: A systematic review.Val66Met Polymorphism and Gamma Band Disruption in Resting State Brain Functional Connectivity: A Magnetoencephalography Study in Cognitively Intact Older Females

P2860

Q26783362-066C8C8A-3470-4796-8D19-AEDC3AD5C26F Q26827281-75E7E7EC-ECAB-456F-9E5E-697CC3631518 Q26830467-0D856A81-09B7-41D8-97F0-0E328130E6C2 Q28071845-71643230-BAB8-42D8-B416-0E23ACE6BE4E Q28538189-FCD9BF6E-7404-4B65-B584-90673DDC7214 Q28650395-9315FA69-9F20-4D4A-9F44-DEC45E4C3A0A Q30374487-35F73B01-CF7B-4329-9553-CC40EBFDF084 Q31162702-381679A6-AE4C-413B-8BFB-D0B94758E5B7 Q33745149-55FB1C8B-3573-4AB2-90D3-7E53C58303C8 Q33779117-BCCDCEBE-7892-4CDC-BE02-5F9D4AA45417 Q34849048-0E75BD68-5FD8-40DF-B07D-EAACE3DE8661 Q35006125-56132FCF-D2B9-4E8B-B2FB-12B42E6DC969 Q35086470-69276A9E-5E36-4F03-86DB-9A9A7EF657E4 Q35753185-F2D2116F-2B76-4B98-8324-C9055CA2F80B Q36031233-39890EC9-6C05-4F29-B64A-70DCEEC73F3A Q36594552-38FA7373-CA6D-4C92-803B-A90345FABC2F Q37109482-FD42B430-9E60-4F76-AE3F-ECF5782A2045 Q38178373-A43E6EFD-4CF7-48C7-8BE1-FF06E13D0944 Q38263685-ED5F56F5-EDBB-4500-81A8-53F7722D0BD0 Q38891562-8CB69139-7F14-4318-A446-2B2D782D2F5D Q39128635-73E8C1F3-9998-4F1B-9EF1-EA5015CF5101 Q39493228-C4962334-9CE8-448F-9A5E-35B18AE93E66 Q41831293-50DFC1DF-1193-4887-A32C-0EAEFA29B177 Q42655796-718860E0-B102-472A-BD52-2293C8909E15 Q46093334-7B6FC928-1E18-4074-86CF-5E7C515DDC17 Q47549663-355548E2-8A92-44C6-A3F1-F017CA24CE4E Q48018148-69091BE3-7167-4D68-8F13-ECFB150B74A4 Q48122774-0A82FE77-EC04-4974-9BA9-9A6AA78F07F6 Q48190312-7D21CE3A-AA98-47F6-B7A4-D7634D6628F2 Q48495456-7D876D86-F1A1-4D28-8A27-9B74AACFF87B Q50531667-8E0A6C38-FA1F-4D03-9C81-559AEA1D37DA Q51767352-35DE5D68-3928-4102-A128-D337915EF960 Q53396798-CCA94FD3-17EC-4A5A-8820-CAA7672F3229 Q55092027-F583CAA8-B262-4E47-A302-F6F81AF7CC15 Q55690942-7F38ED02-EF6E-4028-B4CB-CD8E6ED70085 Q58586784-AC04F1EA-A137-4E4F-9788-A86D7DD10169

P2860

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

http://www.wikidata.org/entity/Q45356235

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

@en

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

@nl

type

label

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

@en

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

@nl

prefLabel

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

@en

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

@nl

P1433

Q45356235-F06EDDD9-F022-404F-92D6-5F07DD49BA30

P1476

Q45356235-82D7C53A-D377-4121-8037-4A6FDDC112E4

P2093

Q45356235-12AAF7BE-BDFD-4376-BE39-8B9683405840

Q45356235-20BAD35C-66A1-43FC-8879-B8164A07B54A

Q45356235-469419CB-79F0-437F-9630-8A45F60F51BA

Q45356235-62AD625F-1CE5-40B4-95A8-FE26DE6954FA

Q45356235-6326FD52-2041-40FE-B686-9DB74486A9B4

Q45356235-745D36B2-C405-471D-99A8-959495CB1A6D

Q45356235-9E6C85AE-B1AF-4E6E-9638-4EF4BCEB7520

Q45356235-BCBC6298-80DD-42E1-964E-E57ACC9B4A71

Q45356235-D9E13FA5-D7C6-41B8-9C79-B883304067AB

Q45356235-DFF5E80A-1A24-4073-9FE1-A9DD74513F94

P304

Q45356235-8B375986-DD0F-4CDE-AF3B-C3F54ACE7728

P31

Q45356235-33A8DFF0-77F4-49E8-8781-F5F71D57A752

P356

Q45356235-41A22E80-EFD3-4F85-83B5-F261B0265AF8

P433

Q45356235-E8AB5B26-E6DD-4539-856C-E19BFE40D4FE

P478

Q45356235-7901FE01-C7AF-4030-86A4-1968018D9184

P50

Q45356235-12409938-7958-4271-B0C9-DB649A83CB6D

Q45356235-3EA97EAB-2DCE-4301-9F7D-94F42A508561

Q45356235-629729B6-FF87-401F-A352-5069BF5C59B2

Q45356235-66EB49CC-B79B-4BB8-81A1-36F00FBA5899

Q45356235-DCDB214C-59C7-41A1-83B8-620A482B90C5

Q45356235-F10774D9-F12B-4F68-A49F-AA40DA17F95A

Q45356235-F278B865-D0B7-4EEB-9A86-86D86C31AE30

P577

Q45356235-5AA2945A-E7B9-4BF4-9701-D399278F1BC8

P5875

Q45356235-6A4BC400-9A0A-4290-A652-97BC228AA753

P698

Q45356235-616CA4FD-16D5-4ED8-93E8-1ACB4BD73134

P921

Q45356235-BBFD6CFC-97D2-482C-AA74-9169FB7E6E1E

P356

J.NEUROBIOLAGING.2013.05.006

P1433

Neurobiology of Aging

P1476

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.

@en

P2093

Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group

http://www.w3.org/2001/XMLSchema#string

Christopher C Rowe

http://www.w3.org/2001/XMLSchema#string

David Ames

http://www.w3.org/2001/XMLSchema#string

David Darby

http://www.w3.org/2001/XMLSchema#string

Karra D Harrington

http://www.w3.org/2001/XMLSchema#string

Kathryn A Ellis

http://www.w3.org/2001/XMLSchema#string

Pradeep J Nathan

http://www.w3.org/2001/XMLSchema#string

Ralph N Martins

http://www.w3.org/2001/XMLSchema#string

Robert H Pietrzak

http://www.w3.org/2001/XMLSchema#string

Victor L Villemagne

http://www.w3.org/2001/XMLSchema#string

P304

2457-2464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROBIOLAGING.2013.05.006

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Colin L. Masters

Pierrick Bourgeat

Olivier Salvado

Peter J. Snyder

P577

2013-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261437383

http://www.w3.org/2001/XMLSchema#string

P698

23769397

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease